Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 12, 2017 - Issue
Submit an article Journal homepage
63
Views
12
CrossRef citations to date
0
Altmetric
Original Research

A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy

Douglas Mapel1 Health Services Research Division, Lovelace Clinic Foundation, Albuquerque, NM, USACorrespondence[email protected]
,
François Laliberté2 Groupe d’analyse, Montreal, QC, Canada
,
Melissa H Roberts1 Health Services Research Division, Lovelace Clinic Foundation, Albuquerque, NM, USA;3 Department of Pharmacy Practice and Administrative Sciences, University of New Mexico, College of Pharmacy, University of New Mexico, Albuquerque, NM
,
Susan R Sama4 Research Department, Reliant Medical Group, Worcester, MA
,
Devi Sundaresan4 Research Department, Reliant Medical Group, Worcester, MA
,
Dominic Pilon2 Groupe d’analyse, Montreal, QC, Canada
,
Patrick Lefebvre2 Groupe d’analyse, Montreal, QC, Canada
,
Mei Sheng Duh5 Analysis Group, Boston, MA
&
Jeetvan Patel6 US Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC, USA
 show all
Pages 1825-1836 | Published online: 21 Jun 2017

Figures & data

Table 1 Baseline demographics and clinical characteristics

Table 2 Baseline demographics and clinical characteristics in subsets of patients

Table 3 Summary of baseline exacerbations

Table 4 Summary of baseline exacerbations in subsets of patients

Table 5 Time to initiation of open-triple therapy at 12 months (post-index date)

Figure 1 Kaplan–Meier curve to show rates of open-triple therapy initiation at 12 months (post-index date).

Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.

Figure 1 Kaplan–Meier curve to show rates of open-triple therapy initiation at 12 months (post-index date).Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.

Figure 2 Kaplan–Meier curve to show rates of open-triple therapy initiation at 12 months (post-index date) in patients with pulmonary-function testing information.

Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.

Figure 2 Kaplan–Meier curve to show rates of open-triple therapy initiation at 12 months (post-index date) in patients with pulmonary-function testing information.Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.

Figure 3 Kaplan–Meier curve to show rates of open-triple therapy initiation at 12 months (post-index date) in patients with asthma.

Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.

Figure 3 Kaplan–Meier curve to show rates of open-triple therapy initiation at 12 months (post-index date) in patients with asthma.Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.

Figure 4 Kaplan–Meier curve to show rates of open-triple therapy initiation at 12 months (post-index date) in patients without asthma.

Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.
Figure 4 Kaplan–Meier curve to show rates of open-triple therapy initiation at 12 months (post-index date) in patients without asthma.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.